Source: [ctgov](https://clinicaltrials.gov/study/NCT07583017)
Authors: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Venue: NOT_YET_RECRUITING · 2026-05-13
Abstract
Obesity is characterized by gut microbiota dysbiosis, in which beneficial metabolites such as butyrate are reduced. Butyrate is a short-chain fatty acid produced by microbial fermentation that plays a key role in maintaining intestinal barrier integrity, regulating immune responses, and supporting mitochondrial function. Its depletion contributes to disruption of the intestinal barrier, facilitating the translocation of bacterial components and promoting systemic inflammation mediated by immune cell activation, like monocytes. This chronic inflammatory state is associated with mitochondrial dysfunction and impaired cellular bioenergetics. Butyrate has been investigated for its anti-inflammatory and metabolic effects, however, its direct impact on monocyte mitochondrial function and its relationship with gut microbiota composition in humans remains unclear.
This randomized, double-blind, placebo-controlled trial will evaluate the effect of oral calcium butyrate supplementation (1000 mg
AI relevance (5/5): Directly addresses butyrate's role in intestinal barrier integrity, immune regulation, and gut microbiota dysbiosis—core mechanisms of mucosa homeostasis.
--- *Draft auto-created from Suggestions queue. Polish the body, set is_real=true when verified, and publish via `INSERT INTO bionoia_published` when ready for /public/.*